David Reparaz
Overview
Explore the profile of David Reparaz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Senent Y, Remirez A, Reparaz D, Llopiz D, Celias D, Sainz C, et al.
Cancer Immunol Res
. 2024 Dec;
13(3):384-399.
PMID: 39666368
The precise mechanisms by which the complement system contributes to the establishment of an immunosuppressive tumor microenvironment and promotes tumor progression remain unclear. In this study, we investigated the expression...
2.
Vercher E, Covo-Vergara A, Conde E, Hernandez-Rueda M, Elizalde E, Mancheno U, et al.
Hepatology
. 2024 Nov;
PMID: 39601444
Background And Aims: Glypican-3 (GPC3) is a promising target for T-cell therapy in HCC. While chimeric antigen receptor (CAR) T cells targeting GPC3 have demonstrated therapeutic efficacy, their effectiveness is...
3.
Passelli K, Reparaz D, Kinj R, Herrera F
Br J Radiol
. 2024 Jun;
97(1160):1378-1390.
PMID: 38833685
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment; yet their efficacy remains variable across patients. This review delves into the intricate interplay of tumour characteristics contributing to resistance against ICI...
4.
Reparaz D, Casares N, Fuentes A, Navarro F
Methods Cell Biol
. 2024 Mar;
185:79-97.
PMID: 38556453
Hepatocellular carcinoma (HCC) is one of the most prevalent malignant neoplasms. Current treatments for HCC, such as tyrosine kinase inhibitors, have limited efficacy, highlighting the urgent need for better therapies....
5.
Passelli K, Reparaz D, Herrera F
Int Rev Cell Mol Biol
. 2023 Jul;
378:137-156.
PMID: 37438016
Therapeutic monoclonal antibodies blocking different immune checkpoints, have demonstrated efficacy against a wide variety of solid tumors. The exclusion or absence of lymphocytes within the tumor microenvironment (TME) is one...
6.
Aparicio B, Reparaz D, Ruiz M, Llopiz D, Silva L, Vercher E, et al.
Front Immunol
. 2022 Nov;
13:985886.
PMID: 36405725
Immune checkpoint inhibitor (ICI)-based immunotherapy in triple negative breast cancer (TNBC) is achieving limited therapeutic results, requiring the development of more potent strategies. Combination of ICI with vaccination strategies would...
7.
Reparaz D, Ruiz M, Silva L, Aparicio B, Egea J, Guruceaga E, et al.
Front Immunol
. 2022 Oct;
13:991311.
PMID: 36300124
Vaccination using optimized strategies may increase response rates to immune checkpoint inhibitors (ICI) in some tumors. To enhance vaccine potency and improve thus responses to ICI, we analyzed the gene...
8.
Reparaz D, Hommel M, Navarro F, Llopiz D
Int Rev Cell Mol Biol
. 2022 Aug;
371:1-14.
PMID: 35964997
Dendritic cells (DCs) are professional antigen presenting cells that play an important role in the induction of T cell responses. Different subsets (cDC1s, cDC2s, pDCs, and moDCs) were described based...
9.
Navarro F, Casares N, Martin-Otal C, Lasarte-Cia A, Gorraiz M, Sarrion P, et al.
Oncoimmunology
. 2022 May;
11(1):2070337.
PMID: 35529677
The high metabolic activity and insufficient perfusion of tumors leads to the acidification of the tumor microenvironment (TME) that may inhibit the antitumor T cell activity. We found that pharmacological...
10.
Reparaz D, Aparicio B, Llopiz D, Hervas-Stubbs S, Sarobe P
Int J Mol Sci
. 2022 Feb;
23(4).
PMID: 35216137
Immune checkpoint inhibitors (ICI) have been used as immunotherapy for hepatocellular carcinoma (HCC) with promising but still limited results. Identification of immune elements in the tumor microenvironment of individual HCC...